Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Miriam Mattoscio
Observed names:
M. Mattoscio,
Mattoscio Miriam,
Mattoscio, Miriam
Institution:
Barking, Havering And Redbridge University Hospitals NHS Trust
Observed institutions:
University of Verona,
Barking, Havering And Redbridge University Hospitals NHS Trust,
University of Padua,
Imperial College Healthcare NHS Trust,
Queen's Medical Center,
Queen's Hospital,
Queen's Hospital,
Imperial College London,
University of Genoa
show all 9
ORCID:
0000-0002-8426-194X
Observed ORCID:
0000-0002-8426-194X
OpenAlex ID:
A5091551192
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
2021
·
Maria T. Cencioni
, Miriam Mattoscio
, et al.
·
Nature Reviews Neurology
·
319
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis
2018
·
Antonio Scalfari
, Chiara Romualdi
, et al.
·
Neurology
·
134
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
2024
·
Xavier Montalban
, Patrick Vermersch
, et al.
·
The Lancet Neurology
·
101
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
2017
·
Graziella Filippini
, Cinzia Del Giovane
, et al.
·
Cochrane Database of Systematic Reviews
·
65
PDF
A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis
2016
·
Alfonso Lema
, Courtney Bishop
, et al.
·
Journal of Neuroimaging
·
56
Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions
2016
·
Courtney A Bishop
, Rexford D Newbould
, et al.
·
NeuroImage Clinical
·
34
PDF
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis
2015
·
Miriam Mattoscio
, Richard Nicholas
, et al.
·
Neurology
·
32
PDF
Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis
2014
·
R.D. Newbould
, R. Nicholas
, et al.
·
NeuroImage Clinical
·
32
PDF
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
2024
·
James Blackstone
, Thomas Williams
, et al.
·
BMJ Open
·
27
PDF
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
2016
·
Graziella Filippini
, Marinella Clerico
, et al.
·
Cochrane Database of Systematic Reviews
·
27
PDF
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial
2025
·
Jeremy Chataway
, Thomas Williams
, et al.
·
The Lancet
·
24
Multiple sclerosis therapy and Epstein–Barr virus antibody titres
2014
·
Joel Raffel
, Ruth Dobson
, et al.
·
Multiple Sclerosis and Related Disorders
·
22
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
2021
·
Kimberley Allen-Philbey
, Stefania De Trane
, et al.
·
Therapeutic Advances in Neurological Disorders
·
12
PDF
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK
2023
·
Benjamin M Jacobs
, Luisa Schalk
, et al.
·
BMJ Open
·
7
PDF
Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds
2026
·
Benjamin Meir Jacobs
, Luisa Schalk
, et al.
·
Neurology
·
6
PDF
PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom
2025
·
Nikos Evangelou
, Miriam Mattoscio
, et al.
·
International Journal of MS Care
·
2
PDF
A recent surge of nitrous oxide misuse around London which merits a public health warning
2023
·
Naveed Malek
, Akın Nihat
, et al.
·
Postgraduate Medical Journal
·
2
PDF
Haematopoietic Stem Cells for the Treatment of MS
2013
·
Sofia Abrahamsson
, Miriam Mattoscio
, et al.
·
Springer eBooks
·
2
Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trial
2026
·
Sean Apap Mangion
, Charles Wade
, et al.
·
medRxiv
·
1
PDF
Cladribine tablets in highly-active relapsing multiple sclerosis real-world effectiveness in UK clinical practice (CAMELOT-MS)
2024
·
Brownlee Wallace
, Rog David
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
1
125 Real world data evaluating efficacy and safety of oral cladribine for multiple sclerosis
2022
·
Moneeb Nasir
, Plaxedes Rabvukwa
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
1
Circulating Hematopoietic Stem Cell Numbers during Natalizumab Treatment in Patients with Multiple Sclerosis: Association with Clinical and MRI Variables (P05.194)
2013
·
Miriam Mattoscio
, Richard Nicholas
, et al.
·
Neurology
·
1
Differential Increase of Circulating Haematopoietic Stem Cells (HSC) Following Therapeutic alpha 4-Integrin Blockade in Multiple Sclerosis: Correlation between HSC Mobilization Status and Response to Treatment (IN8-1.006)
2012
·
M. Mattoscio
, R. Nicholas
, et al.
·
Neurology
·
1
Association Between Genetic Ancestry and Multiple Sclerosis Severity
2026
·
Benjamin M. Jacobs
, Emily Tregaskis‐Daniels
, et al.
·
Annals of Neurology
PDF
Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial
2026
·
Thomas Williams
, Nicholas Magill
, et al.
·
Brain Communications
Show more works
View as search
Works count:
38
Citation count:
914
H-index:
12
I10-index:
13
Year
Topic
Type